In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.
, who directs the Yale Alzheimer's Disease Research Center and presented an overview of the study at the meeting.of the National Institute on Aging, who was not involved in the study, called the results"a very small effect."
About one in five people who got lecanemab in the study experienced an adverse event, such as swelling or bleeding in the brain. People also reported symptoms including headaches, visual disturbances, and confusion.Dr. Marwan Sabbagh The apparent success of lecanemab comes after many years of frustration and failure for companies developing drugs designed to clear amyloid from the brain., has received approval from the Food and Drug Administration.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New Alzheimer’s drug shows promise in slowing disease but may contain significant risks, study showsAn experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers report — but it remains unclear how much difference that might make in people’s lives.
Read more »
Study: Alzheimer's drug lecanemab shows moderate benefit for people with mild diseaseA new study released Tuesday showed a closely-watched Alzheimer's drug slowed cognitive decline among people with early signs of the disease also carries safety risks for some patients.
Read more »
New Drug Shows Signs of Slowing Cognitive Decline in Alzheimer's Patients, Study FindsAn experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported -- but it remains unclear how much difference that might make in people’s lives.
Read more »
Study: Alzheimer's drug shows modest success slowing declines in memory, thinkingIn a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.
Read more »
Study: Alzheimer's drug shows modest success slowing declines in memory, thinkingIn a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.
Read more »
Study: Alzheimer's drug shows modest success slowing declines in memory, thinkingThe drug, called lecanemab, reduced the rate of cognitive decline by 27% in a study of nearly 1,800 people in the early stages of Alzheimer's, scientists reported at the Clinical Trials on Alzheimer's Disease meeting in San Francisco.
Read more »